Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQWR4N)

Drug Name
PR001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Gaucher disease 5C56.0Y Phase 1/2 [1]
Parkinson disease 8A00.0 Phase 1/2 [2]
Cross-matching ID
TTD Drug ID
DMQWR4N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Lysosomal acid glucosylceramidase (GBA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AVR-RD-02 DM6ZXAX Gaucher disease 5C56.0Y Phase 2/3 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysosomal acid glucosylceramidase (GBA1) TTCYHJ4 GBA1_HUMAN Not Available [3]

References

1 ClinicalTrials.gov (NCT04411654) An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04127578) A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL). U.S.National Institutes of Health.
3 Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations. J Parkinsons Dis. 2021;11(s2):S183-S188.
4 ClinicalTrials.gov (NCT05815004) Guard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25. U.S.National Institutes of Health.